PD 089828 (Synonyms: EGF/FGF/PDGF Receptor Tyrosine Kinase Inhibitor) |
| Katalog-Nr.GC44583 |
PD 089828 ist ein ATP-kompetitiver Inhibitor von FGFR-1, PDGFR-β und EGFR (IC50s \u003d 0,15, 1,76 bzw. 5,47 µM) und ein nicht-kompetitiver Inhibitor von c-Src-Tyrosinkinase (IC50 \u003d 0,18 µM). PD 089828 hemmt auch MAPK mit einem IC50 von 7,1 µM. PD 089828 hemmt die PDGF-, EGF- und bFGF-vermittelte Tyrosinkinase-Rezeptor-Autophosphorylierung in vitro. PD 089828 hat eine lang anhaltende Zellaktivität.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 179343-17-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 µM). It is selective for these targets over insulin receptor tyrosine kinase, PKC, and CDK4 (IC50s = >50 µM) but does inhibit MAPK (IC50 = 7.1 µM). PD 089828 decreases PDGF-BB-, EGF-, and bFGF-induced phosphorylation of PDGFR, EGFR, and FGFR1, respectively, in a concentration-dependent manner in vitro. It also decreases serum-stimulated growth (IC50 = 1.8 µM after 8 days) and migration (IC50 = 4.5 µM) of rat aortic smooth muscle cells.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *